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Abstract
In the rapidly ageing society in Poland, osteoporosis is a growing epidemiological problem, and osteoporosis-related fractures are a cause 
of chronic disability and considerable increase of death risk. It turns out that 80 to 90% of patients suffering from osteoporosis, including 
osteoporosis accompanied by fractures, do not receive adequate pharmacotherapy. In this paper, a Guideline Working Group of experts 
from the Multidisciplinary Osteoporosis Forum update the existing Polish guidelines concerning the diagnosis and management of os-
teoporosis (last revised in 2013), taking account of the latest literature, availability and reimbursement of drugs, and current health care 
organisation. In the revised guidelines, we still postulate that tasks are divided between primary care doctors (stage I) and specialists in 
osteoporosis management (stage II). We emphasise the necessity of early initiation of pharmacotherapy and rehabilitation in all patients 
with low-energy fractures. We recommend that the 10-year fracture risk should be estimated in all patients (including those without 
fractures) who are over 50 years of age, and that the Polish threshold for therapeutic intervention should be adopted: ≥ 10% for FRAX PL 
calculator. We add strategies of drug choice and therapy monitoring with imaging, and densitometric and biochemical diagnostics. We 
define basic guidelines concerning prevention of falls, rehabilitation, and dietary procedures, and elimination of environmental and other 
fracture risk factors. We point to two vital elements for improving osteoporosis management: 1) strategy of supervision over fractures 
management — Fracture Liaison Service (FLS), and, optimally, 2) strategies of short-term monitoring of the therapeutic efficacy with the 
use of biochemical markers.  (Endokrynol Pol 2017; 68 (5): 604–609)
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Introduction
More than 2 million people within the Polish popula-
tion at the age of over 50 years (every third woman 
and every fifth man) suffer from osteoporosis, in most 
cases — complicated with fractures [1]. In spite of in-
creased mortality, worse quality of life, and higher risk 
of subsequent fractures following the first fracture, only 
10 to 20% of such patients receive pharmacological 
treatment. The number of patients with a high risk of 
the first fracture, who receive pharmacological treat-
ment, is on a similar, unacceptably low level [2].
The purpose of this paper is to update and complete 
the existing Polish guidelines [3, 4] concerning the 
diagnosis and management of osteoporotic patients 
with or without history of fractures, with the aim of 
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improving the existing status of underestimating the 
present osteoporosis-related threats. 
Methods
A group of experts (specialists in rheumatology, ortho-
paedics and traumatology, internal medicine, geriatrics, 
endocrinology, rehabilitation, nephrology, diabetology, 
oncology, biochemistry, and imaging techniques) from 
the Multidisciplinary Osteoporosis Forum performed 
analysis of English-language publications in MEDLINE 
and COCHRANE databases concerning diagnosis, 
prevention, and therapeutic procedures, published 
from 2012 to March 2017. The agreed recommendations 
were preceded by abundant electronic correspondence 
and comments in writing. The task of the group was to 
update the “Guidelines” published in 2013 [3, 4]. The 
guidelines were rated by experts who voted using a 1–10 
(10 = strongest) point scale to assess the “strength” of 
each recommendation in the Polish conditions. The ex-
isting guidelines were referred for review and accepted 
by national consultants in endocrinology, orthopaedics 
and traumatology, geriatrics, rheumatology, internal 
medicine, medical rehabilitation, diabetology, family 
medicine, and public health.
Management strategy
The general strategy is based on comprehensive diag-
nostic and therapeutic management, including division 
of tasks between primary care doctors at stage I and 
specialists treating osteoporosis at stage II. 
First stage
All patients with suspected osteoporosis should be 
subject to selective screening including physical exami-
nation and history-taking, taking account of measure-
ments of height and muscle strength, and assessment 
of clinical factors of fracture risk [including FRAX PL 
(http://www.shef.ac.uk/FRAX/tool.aspx?country=40), 
falls risk factors, and others]. Values < 10% of the 10-
year fracture risk qualify for preventive action or further 
diagnostic procedures, depending on the patient’s 
condition. Ten-year risk ≥ 10% of fractures in major 
locations, or ≥ 3% concerning neck of the femoral bone, 
qualify the patient for further osteoporosis diagnosis 
and comprehensive treatment in a specialist centre 
(stage II) [4]. 
Major fracture locations include: proximal femur 
(hip), vertebrae, proximal humerus, pelvis, distal radial 
bone [2, 4, 5]. 
It should be stressed that each previous low-
energy fracture in the hip region and in other major 
locations highly increases the risk of subsequent 
fractures and is an absolute indication for fast initia-
tion of comprehensive treatment (orthopaedic, phar-
macological, analgesic, rehabilitation, and dietary 
interventions) [6]. 
Second stage
Specialist stage, includes differential diagnostics 
(secondary osteoporosis, other bone diseases, comor-
bidities) and detailed assessment of all fracture risks, 
including sarcopenia, for their possible elimination and 
for patient education. The specialist’s task is to choose 
an effective pharmacotherapy based on densitometry 
(dual-energy X-ray absorptiometry — DXA) measure-
ments, serum Vitamin D [25(OH)D] levels, together 
with calcium balance assessment and, possibly, bone 
turnover markers. 
A fundamental role in choosing medication is played 
by in-label indications as well as contraindications, 
reimbursement options, and patient preferences [7]. 
It is also important to decide on adjuvant treatment, 
rehabilitation, fall prevention, calcium and vitamin D 
supplementation, diet modification, and a programme 
of therapy monitoring (Fig. 1). 
In the case of a patient without low-energy frac-
tures, pharmacotherapy is initiated by a specialist if 
a ≥ 10% fracture risk in major locations is confirmed 
in the 10-year perspective (calculated by FRAX BMD) 
and/or T-score upon DXA is ≤ –2.5 SD regarding hip or 
lumbar spine. 
In the case of low-energy fractures, orthopaedic 
treatment should be accompanied by pharmacologi-
cal treatment, followed by rehabilitation. It is always 
recommended that DXA and detailed diagnostic pro-
cedures are performed in order to exclude or confirm 
secondary osteoporosis.
In the course of treatment, it is recommended that 
the efficacy and safety of therapy is regularly monitored 
[8, 9], and that the already existing and possibly occur-
ring new fracture risk factors are periodically verified. 
Control of the patient’s adherence to therapy, assess-
ment of therapy efficacy, decision on a drug holiday, or 
drug switching depend on applied medication [8, 10], 
periodic densitometric examination, optimally, assess-
ment of bone markers and X-ray examination, e.g. 
when the patient’s height decreases significantly. In 
secondary osteoporoses, applied procedures should be 
subject to the requirements of the underlying disease 
management [9]. 
In patients with a lower fracture risk (fracture risk 
assessed by FRAX PL ≤ 5%), it is recommended that 
dietary and lifestyle prevention measures are initi-
ated [4, 5, 7].
606
Guidelines for the diagnosis and management of osteoporosis in Poland. Update 2017 Roman Lorenc et al.
SZ
K
O
LE
N
IE
 
PO
D
YP
LO
M
O
W
E
Guidelines
1. We postulate that low-energy hip fractures in 
women over 50 years of age and men over 65 years 
of age, as well as every previous low-energy frac-
ture in other major locations (after excluding other 
causes), with already existing osteopaenia (DXA, 
T-score < –1.5), is an obvious basis for diagnosing 
osteoporosis, and an indication for early initia-
tion of comprehensive treatment (orthopaedic, 
pharmacological, analgesic, rehabilitation, and 
dietary) [“strength” 8.8].
2. We recommend, that immediately after surgical or 
conservative treatment of a low-energy fracture, 
the orthopaedic surgeon (traumatologist) initi-
ates either oral or parenteral pharmacotherapy, 
or refers the patient to a competent osteoporosis 
therapy centre, in order to reduce the risk of 
subsequent fractures [9.1].
3. In patients of both sexes over 50 years of age, 
a high fracture risk in 10-year perspective (FRAX 
BMD ≥ 10%) or T-score ≤ –2.5 for hip or vertebrae 
L1–L4 is also the basis for diagnosing osteoporosis, 
and for initiation of treatment [8.1] 
4. We postulate that the primary care doctor and/ 
/or family doctor (stage I), based on physical 
examination (including height measurement), 
contributory history of fractures and falls, and 
fracture risk assessment by means of FRAX BMI 
for the Polish population, is entitled to: identify 
patients at risk of fractures and refer them to an 
outpatient osteoporosis clinic or other specialist 
engaged in osteoporosis management. For pa-
tients with a low fracture risk and without past 
fractures, the main task of the primary care doctor 
is to carry out preventive measures and patient 
education [7.5].
5. Tasks of the primary care doctor and/or family 
doctor should include continuation and moni-
toring of treatment initiated by the outpatient 
osteoporosis clinic or by other specialists, veri-
fication of possible adverse effects of drugs, and 
identification and, possibly, elimination of new 
fracture risk factors [7.3].
6. We recommend that the tasks of the specialist 
treating osteoporosis (stage II) should include 
confirmation of occurred fractures, identification 
of other existing fracture risks, and an ultimate 
decision on comprehensive therapy based on dif-
ferential diagnosis, densitometry, bone turnover 
(optimally), determination of calcium-phosphate 
balance including 24-hour urinary calcium, and 
serum vitamin D levels [8.3].
7. Densitometry (DXA) remains the “gold stand-
ard” in osteoporosis diagnosis. The World 
Health Organisation (WHO) defines the fol-
lowing densitometric criteria for diagnosing 
osteoporosis on the basis of BMD measurement 
by means of DXA of the femoral neck (or spine) 
in postmenopausal women (T-score is expressed 
as the number of standard deviations from the 
reference point, which is the peak bone mineral 
density). 
• 1) T score > −1 SD — normal value,
• 2) T score from −1 to –2.5 SD — osteopaenia,
• 3) T score ≤ −2.5 SD — osteoporosis,
• 4) T score ≤ −2.5 SD plus an osteoporotic frac-
ture — advanced osteoporosis.
Figure 1. Overall algorithm of diagnostic and therapeutic procedures in postmenopausal and senile osteoporosis
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Similar criteria have been adopted also for men 
> 50 years of age [8.1].
8. In densitometry-based diagnostics in younger 
patients (< 40 years old), the Z-score should be 
taken into account, while the final diagnosis, 
assessment of fracture risk factors (FRAX is not 
applied in persons < 45 years old), and the choice 
of therapy should be decided by the specialist in 
cooperation with the patient [8.6].
9. Current guidelines concerning harmonisation, 
standardisation, and automation of bone markers 
restrict the applied markers to CTX (C-terminal 
telopeptide of type I collagen) as a bone resorption 
marker, and PINP (N-terminal propeptide of type 
I procollagen) as a bone formation marker. Marker 
measurement is useful in therapy monitoring, 
“drug holidays”, assessment of fracture risks, 
and in suspicion of malignancies. Postulates for 
marker testing and interpretation are defined by 
adequate GLP requirements [7.4].
10. An important role in diagnostics and therapy is 
played by the assessment of the patient’s general 
condition, particularly of his/her musculosceletal 
system and condition of muscles (sarcopenia, 
myopathies, frailty syndrome, falls risk), evalu-
ated mainly by means of measuring the muscle 
mass, walking speed, handgrip strength, and get 
up and go test [9.1].
11. Choice of a drug (stage II) of the highest anti-
fracture effectiveness, individually for the patient, 
should be made by a specialist on the basis of 
BMD measurement and biochemical test results, 
taking account of in-label indications, possible 
contraindications, and therapy costs. 
 The specialist’s tasks also include: definition of 
a therapy monitoring protocol, patient’s educa-
tion, and elimination of modifiable fracture risk 
factors [8.8 ].
12. Osteoporosis diagnostics and treatment in men 
of over 50 years of age does not differ substan-
tially from those in postmenopausal women. 
Similar drugs are used for treatment, although 
some of them have not been approved for use 
in men (e.g. ibandronate, raloxifene). Adminis-
tration of testosterone in men with deficiency 
of the hormone does improve the BMD result 
and general performance status, but the fracture 
risk-reducing effect of such therapy has not been 
proven [8.8].
13A. Bisphosphonates are the most commonly used 
anti-resorptive drugs, with the best established 
anti-fracture effect regarding spine, hip, and other 
non-vertebral locations. Efficacy of bisphospho-
nate therapy depends on prior obtaining and 
maintenance of normal serum 25(OH) D levels 
and calcium-phosphate balance [8.1].
13B. As well as regular yearly monitoring of therapy 
(BMD measurement in the same location by 
means of the same device), after three years of 
intravenous bisphosphonate administration, or 
after five years of oral bisphosphonate administra-
tion, it is necessary to verify the foregoing efficacy, 
safety, and possible purpose of further therapy, to 
consider the need of drug modification or drug 
holiday. Efficacy of medication can be evaluated 
after three months on the basis of bone marker 
measurements and comparison of the results to 
baseline values. In a longer perspective, it can be 
evaluated by BMD measurement [8.8].
13C. Therapy with bisphosphonate(s) in therapeutic 
doses (alendronate, risedronate, ibandronate, 
zoledronate) is considered to have failed if a new 
fracture occurs after 12 months of the therapy, or 
if the BMD value decreases after 12 months of 
the therapy in comparison to the baseline and 
the decrease is greater than the least significant 
change as measured in the same location [8.4].
14.  Denosumab is an antibody inhibiting the matu-
ration and function of osteoclasts, and it can be 
used as a first-line drug or when other therapies 
have been unsuccessful in osteoporotic patients 
of both sexes. It can be administered in sequential 
therapy after an anabolic; it can be also given 
to patients with severe renal failure. Its anti-re-
sorptive effect is reversible, and the fracture risk 
may increase when the drug is discontinued; 
therefore, drug holidays are not recommended, 
and where it is necessary to stop the therapy, the 
patient should be prescribed any other anti-re-
sorptive drug [8.5].
15.  Despite of their established anti-fracture effect, 
also in severe secondary osteoporoses, parathy-
roid hormone (PTH) derivatives, e.g. teriparatide 
(anabolic drugs), are rarely used because of their 
high cost. When the drug is discontinued (dura-
tion of therapy is limited to 24 months), treatment 
should be continued with the use of another an-
ti-resorptive drug (bisphosphonate, denosumab) 
as a sequential therapy. Administration of PTH 
derivatives immediately after anti-resorptive 
drugs is not recommended [8.9].
16.  Although it reduces the fracture risk, hormone re-
placement therapy (HRT — oestrogen-progestagen) 
in postmenopausal women is currently not recom-
mended for the treatment of osteoporosis. Similarly, 
drugs from the SERM class (e.g. raloxifene), which 
reduce the risk of vertebral fractures, are used to 
a limited extent due to their adverse effects [8.2].
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17.  Strontium ranelate is a dual-action drug, with an 
established anti-fracture effect in all locations. It 
is efficient in patients of both sexes with osteopae-
nia, osteoporosis, and in the oldest patients (> 80 
years of age). Due to possible thromboembolic 
complications and increased risk of cardiovascular 
diseases, the European Medicines Agency (EMA) 
imposed limits in its use [8.4].
18.  An important role in the prevention and treatment 
of osteoporosis is played by optimal (diet and/ 
/or supplements) intake of calcium (about 1200 
mg/day), protein (1.2 g/kg of body weight /day), 
potassium (about 3500 mg/day), and magnesium 
(> 300 mg/day). The necessary component of 
osteoporosis prevention and treatment is an ad-
equate Vitamin D supply (minimum 800 IU/day), 
while the efficacy of pharmacotherapy depends 
on optimal serum levels of 25(OH)D, and com-
pensation of the calcium–phosphate balance [9].
19.  In the case of secondary osteoporoses, it is vital 
to effectively manage the underlying disease. 
Considering the complexity of individual diseas-
es, we recommend individualised management, 
possibly with reduction or elimination of osteopo-
rosis-causing drugs, supplementation of nutrition 
deficiencies, kinesiotherapy, and elimination of 
additional fracture risk factors [8.8].
20.  An especially common iatrogenic secondary 
osteoporosis is glucocorticoid-induced osteopo-
rosis (GIO) caused by chronic administration of 
glucocorticoids. We recommend that fracture risk 
should be determined and followed by preventive 
actions or therapy in all patients receiving predni-
sone (or equivalent) in a daily dose > 2.5 mg for 
> 3 months. Preventive administration of bis-
phosphonate should be considered in patients 
over 50 years old with fracture risk factors, who 
receive > 5 mg/day prednisone for > 3 months, 
while such a procedure should be initiated oblig-
atorily in patients over 65 years of age, receiving 
≥ 7.5 mg/day, even if they present no other frac-
ture risk factors. A previous fracture is always an 
indication to initiate therapy [8.8]. 
21A. Fracture risk is higher in diabetic patients. In the 
case of type 1 diabetes, densitometric examination 
should be performed after five years from the disease 
diagnosis, and repeated every two to five years, de-
pending on its results. In type 2 diabetes, the fracture 
risk may not correspond with the BMD value [8.1].
21B. The FRAX calculator is not suited for assessment 
of the fracture risk in young patients with type 1 
diabetes; it can be more useful with older patients 
with type 2 diabetes, but the usefulness of the tool 
in such patients has not been verified [8.2].
22. Osteoporosis secondary to endocrinopathies, 
hyper- and hypothyroidism, hyperparathyroid-
ism, diseases of adrenal cortex and hypothalam-
ic-pituitary axis, and hypogonadism requires 
prior specialist endocrinological treatment of the 
underlying disease [8.8].
Table I. Anti-fracture efficacy of osteoporosis treatments (according to Reginster JY et al. Drugs 2011; 71: 65–78)
FORM/DOSE DOSAGE POSTMENOPAUSAL OSTEOPOROSIS MALE 
OSTEOPOROSIS
GIO
REDUCTION 
OF 
VERTEBRAL 
FRACTURES
REDUCTION 
OF HIP 
FRACTURES
REDUCTION 
OF NON-
VERTEBRAL 
FRACURES
ALENDRONATE Tablets 70 mg orally 1 × per week YES YES YES YES YES
IBANDRONATE Tablets 150 g orally 1 × per month YES NO NO NO NO
Pre-filled syringe  
3 mg/3 ml
i.v. 1 × every three 
months
RISEDRONATE Tablets 35 mg orally 1 × per week YES YES YES YES YES
ZOLEDRONATE Solution 5 mg/ 
/100 ml
i.v. 1 × per year YES YES YES YES YES
DENOSUMAB Pre-filled syringe 60 
mg/1 ml
s.c. 1 × every six 
months
YES YES YES YES NO
RALOXIFENE Tablets 60 mg orally 1 × daily YES NO NO NO NO
TERIPARATIDE* Solution 2 µg/ 
/80 µl — pen 3 ml
s.c. 1 × daily YES NO YES YES YES
STRONTIUM 
RANELATE*
Granulate for oral 
suspension 2 g
orally 1 × per daily YES YES YES YES NO
GIO — glucocorticosteroid-induced osteoporosis 
*currently withdrawn from Poland
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23. Due to the complex nature of calcium-phosphate 
metabolism disorders and diversity of bone lesion 
forms in each type of renal osteodystrophy, mana-
gement of patients with chronic kidney disease 
(CKD), including dialysed patients, requires broad 
biochemical diagnostics and, in some cases, bone 
biopsy with histomorphometric assessment. CKD 
patients should be diagnosed and attended in 
specialist centres only [8.5].
24. A special group comprises patients with chronic 
gastrointestinal diseases, patients after bariatric 
surgeries, anorexics, persons following extreme 
vegan diets, etc. In such cases, both gastroen-
terological treatment and a dietician’s (and 
sometimes a psychologist’s) co-operation are 
essential [8.6].
25. An important component of patient care at all 
stages of osteoporosis treatment is comprehensive 
rehabilitation and prevention of falls [8.8].
26. Patients with moderate risk of fractures (10–5%) 
may need further evaluation. Prevention of frac-
tures should involve all patients, including those 
with a low fracture risk (< 5%). A healthy, active 
lifestyle, elimination of smoking and alcohol 
abuse, proper diet, reduction of the use of drugs 
that increase fracture risk, prevention of falls 
and injuries, and adequate social education are 
fundamental conditions for the risk reduction of 
osteoporosis and its complications [9.3].
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